Di Meo Ashley, Saleeb Rola, Wala Samantha J, Khella Heba W, Ding Qiang, Zhai Haiyan, Krishan Kalra, Krizova Adriana, Gabril Manal, Evans Andrew, Brimo Fadi, Pasic Maria D, Finelli Antonio, Diamandis Eleftherios P, Yousef George M
Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Oncotarget. 2017 Dec 8;9(2):2092-2104. doi: 10.18632/oncotarget.23162. eCollection 2018 Jan 5.
Renal cell carcinoma (RCC) constitutes an array of morphologically and genetically distinct tumors the most prevalent of which are clear cell, papillary, and chromophobe RCC. Accurate distinction between the typically benign-behaving renal oncocytoma and RCC subtypes is a frequent challenge for pathologists. This is critical for clinical decision making. Subtypes also have different survival outcomes and responses to therapy. We extracted RNA from ninety formalin-fixed paraffin-embedded (FFPE) tissues (27 clear cell, 29 papillary, 19 chromophobe, 4 unclassified RCC and 11 oncocytomas). We quantified the expression of six miRNAs (miR-221, miR-222, miR-126, miR-182, miR-200b and miR-200c) by qRT-PCR, and by hybridization in an independent set of tumors. We developed a two-step classifier. In the first step, it uses expression of either miR-221 or miR-222 to distinguish the clear cell and papillary subtypes from chromophobe RCC and oncocytoma (miR-221 AUC: 0.96, 95% CI: 0.9132-1.014, < 0.0001 and miR-222 AUC: 0.91, 95% CI: 0.8478-0.9772, < 0.0001). In the second step, it uses miR-126 to discriminate clear cell from papillary RCC (AUC: 1, < 0.0001) and miR-200b to discriminate chromophobe RCC from oncocytoma (AUC: 0.95, 95% CI: 0.8933-1.021, < 0.0001). hybridization showed a nuclear staining pattern. miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by hybridization. miRNA expression could distinguish RCC subtypes and oncocytoma. miRNA expression assessed by either PCR or hybridization can be a clinically useful diagnostic tool to complement morphologic renal tumor classification, improving diagnosis and patient management.
肾细胞癌(RCC)由一系列形态和基因上不同的肿瘤组成,其中最常见的是透明细胞癌、乳头状癌和嫌色细胞癌。准确区分通常表现为良性的肾嗜酸细胞瘤和RCC亚型对病理学家来说是一个常见的挑战。这对临床决策至关重要。不同亚型的生存结果和对治疗的反应也有所不同。我们从90个福尔马林固定石蜡包埋(FFPE)组织中提取了RNA(27个透明细胞癌、29个乳头状癌、19个嫌色细胞癌、4个未分类的RCC和11个嗜酸细胞瘤)。我们通过qRT-PCR以及在另一组独立肿瘤中的杂交来定量六种miRNA(miR-221、miR-222、miR-126、miR-182、miR-200b和miR-200c)的表达。我们开发了一种两步分类器。第一步,它使用miR-221或miR-222的表达来区分透明细胞癌和乳头状癌亚型与嫌色细胞癌和嗜酸细胞瘤(miR-221的AUC:0.96,95%CI:0.9132 - 1.014,P < 0.0001;miR-222的AUC:0.91,95%CI:0.8478 - 0.9772,P < 0.0001)。第二步,它使用miR-126来区分透明细胞癌和乳头状癌(AUC:1,P < 0.0001),并使用miR-200b来区分嫌色细胞癌和嗜酸细胞瘤(AUC:0.95,95%CI:0.8933 - 1.021,P < 0.0001)。杂交显示出核染色模式。通过杂交,miR-126、miR-222和miR-200b在各亚型之间存在显著差异表达。miRNA表达可以区分RCC亚型和嗜酸细胞瘤。通过PCR或杂交评估的miRNA表达可以成为一种临床上有用的诊断工具,以补充形态学肾肿瘤分类,改善诊断和患者管理。